LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Jennifer A. Chan(Dana-Farber Cancer Institute), Susan M. Geyer(Mayo Clinic), F-S. Ou(Mayo Clinic), Michael V. Knopp(University of Cincinnati), Spencer C. Behr(University of California, San Francisco), Tyler Zemla(Mayo Clinic), Jared D. Acoba(University of Hawaiʻi at Mānoa), Ardaman Shergill(University of Chicago), Edward M. Wolin(Icahn School of Medicine at Mount Sinai), Þorvarður R. Hálfdánarson(Mayo Clinic), Nikolaos A. Trikalinos(Washington University in St. Louis), Bhavana Konda(The Ohio State University), N. Vijayvergia(Fox Chase Cancer Center), N.A. Dasari(The University of Texas MD Anderson Cancer Center), J. Strosberg(Moffitt Cancer Center), Elise C. Kohn(National Cancer Institute), Matthew H. Kulke(Boston University), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Jeffrey A. Meyerhardt(Dana-Farber Cancer Institute)
Cited by 27Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis